小分子化合物抗病毒治疗丙型肝炎肝硬化

doi:10.3969/j.issn.1672-5069.2016.04.004

Abstract

Zhang Xiaxia, Xu Xiaoyuan. Renewed regimen of direct-acting antiviral agents in treatment of patients with hepatitis C-induced liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 398-400.

References

[1] Coppola N,Minichini C,Starace M,et al:Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. J Med Virol,2,16.doi:10.1002/jmv.24527[ahead of print].
[2] Tamori A,Enomoto M,Kawada N. Recent advances in antiviral therapy for chronic hepatitis C. Mediators Inflamm,2016,2016:6841628.doi:10.1155/2016/6841628.
[3] Panel AIHG. Hepatitis C guidance:AASLD-IDSA recommendations for testing,managing,and treating adults infected with hepatitis C virus. Hepatology,2015,62:932-954.doi:10.1002/hep.27950.
[4] Morgan RL,Baack B,Smith BD,et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med,2013,158:329-337.doi:10.7326/0003-4819-158-5-201303050-00005.
[5] Sulkowski MS,Vargas HE,Di Bisceglie AM,et al. Effectiveness of simeprevir plus sofosbuvir,with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology,2016,150:419-429.doi:10.1053/j.gastro.2015.10.013.
[6] Mangia A,Arleo A,Copetti M,et al. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int,2016.doi:10.1111/liv.13069[ahead of print].
[7] Leroy V,Angus P,Bronowicki JP,et al. Daclatasvir,sofosbuvir,and ribavirin for hepatitis C virus genotype 3 and advanced liver disease:A randomized phase III study（ALLY-3+）. Hepatology,2016.doi:10.1002/hep.28473[ahead of print].
[8] Keating GM:Ledipasvir/sofosbuvir:a review of its use in chronic hepatitis C. Drugs,2015,75:675-685.
[9] Manns M,Samuel D,Gane EJ,et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease:a multicentre, open-label,randomised,phase 2 trial. Lancet Infect Dis,2016.doi:10.1016/S1473-3099（16）00052-9[ahead of print].
[10] Poordad F,Schiff ER,Vierling JM,et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology,2016.doi:10.1002/hep.28446[ahead of print].
[11] Foster GR,Irving WL,Cheung MC,et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol,2016.doi:10.1016/j.jhep.2016.01.029[ahead of print].
[12] Wyles D,Pockros P,Morelli G,et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology,2015,61:1793-1797.
[13] Modi AA,Nazario H,Trotter JF,et al. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Liver Transplant,2016,22:281-286.
[14] Papadopoulos N,Deutsch M,Georgalas A,et al. Simeprevir and sofosbuvir combination treatment in a patient with HCV cirrhosis and HbS Beta 0-thalassemia:Efficacy and safety despite baseline hyperbilirubinemia:Case reports. Hematology,2016, 2016:7635128.doi:10.1155/2016/7635128[ahead of print].
[15] Curry MP,Forns X,Chung RT,et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology,2015,148:100-107 e101.
[16] Afdhal N,Reddy KR,Nelson DR,et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New Engl J Med,2014,370:1483-1493.
[17] Andreone P,Colombo MG,Enejosa JV,et al. ABT-450,ritonavir,ombitasvir,and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology,2014,147:359-365-e351.
[18] Lawitz E,Sulkowski MS,Ghalib R,et al. Simeprevir plus sofosbuvir,with or without ribavirin,to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet,2014,384:1756-1765.
[19] Kahveci AS,Tahan V. Sofosbuvir and Velpatasvir:A complete pan-genotypic treatment for HCV patients. Turkish J Gastroenterol,2016,27:205-206.
[20] Feld JJ,Jacobson IM,Hezode C,et al. Sofosbuvir and Velpatasvir for HCV Genotype 1,2,4,5,and 6 Infection. New Engl J Med,2015,373:2599-2607.
[21] Foster GR,Afdhal N,Roberts SK,et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. New Engl J Med,2015,373:2608-2617.
[22] Curry MP,O'Leary JG,Bzowej N,et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. New Engl J Med,2015,373:2618-2628.
[23] Alric L,Bonnet D. Grazoprevir+elbasvir for the treatment of hepatitis C virus infection:Expert opinion. Pharmacotherapy,2016,17:735-742.
[24] Roth D,Nelson DR,Bruchfeld A,et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease（the C-SURFER study）:a combination phase 3 study. Lancet,2015,386:1537-1545.
[25] Chen T,Terrault N. Treatment of chronic hepatitis C in patients with cirrhosis:Current opinion. Gastroenterology,2016,32:143-151.
[26] Hsu CS,Kao JH. Management of hepatitis C patients with decompensated liver disease. Gastroenterol Hepatol,2016:1-10.doi:10.1586/17474124.2016.1143775[ahead of print].

Renewed regimen of direct-acting antiviral agents in treatment of patients with hepatitis C-induced liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[3]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[4]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[5]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[6]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[7]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[8]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[9]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[10]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[11]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[12]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[13]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[14]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.
[15]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.